Vericel Corp Ord Total Assets
Vericel Corp Ord total assets. Based on the latest financial reports, Vericel Corp Ord (VCEL) holds total assets worth $487.97 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Vericel Corp Ord worth for the company's overall valuation and market capitalisation.
Total Assets of Vericel Corp Ord (1995–2025)
Total assets of Vericel Corp Ord from 1995 to 2025. This chart illustrates how Vericel Corp Ord's total assets have evolved over time, based on quarterly financial data. See Vericel Corp Ord stock quote for real-time trading data and today's change.
Vericel Corp Ord - Asset Composition Analysis
Vericel Corp Ord Total Assets Breakdown (December 2025)
Vericel Corp Ord total assets breakdown as of December 2025. Vericel Corp Ord's total assets of $487.97 Million consist of 50.7% current assets and 49.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.5% |
| Accounts Receivable | $84.63 Million | 17.3% |
| Inventory | $17.56 Million | 3.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $5.62 Million | 1.2% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1995–2025)
This chart illustrates how Vericel Corp Ord's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore VCEL net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vericel Corp Ord's current assets represent 50.7% of total assets in 2025, a decrease from 80.3% in 1995.
- Cash Position: Cash and equivalents constituted 20.5% of total assets in 2025, down from 67.2% in 1995.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 1995.
- Asset Diversification: The largest asset category is accounts receivable at 17.3% of total assets.
Vericel Corp Ord Competitors by Total Assets
Key competitors of Vericel Corp Ord based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Vericel Corp Ord - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.03 | 4.23 | 5.48 |
| Quick Ratio | 4.68 | 3.89 | 5.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $198.29 Million | $162.49 Million | $103.98 Million |
Vericel Corp Ord - Advanced Valuation Insights
This section examines the relationship between Vericel Corp Ord's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.88 |
| Latest Market Cap to Assets Ratio | 3.55 |
| Asset Growth Rate (YoY) | 12.8% |
| Total Assets | $487.97 Million |
| Market Capitalization | $1.73 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Vericel Corp Ord's assets at a significant premium (3.55x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Vericel Corp Ord's assets grew by 12.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Vericel Corp Ord (1995–2025)
The table below shows the annual total assets of Vericel Corp Ord from 1995 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $487.97 Million | +12.77% |
| 2024-12-31 | $432.72 Million | +22.36% |
| 2023-12-31 | $353.66 Million | +29.54% |
| 2022-12-31 | $273.00 Million | +12.02% |
| 2021-12-31 | $243.71 Million | +18.53% |
| 2020-12-31 | $205.61 Million | +34.18% |
| 2019-12-31 | $153.24 Million | +29.11% |
| 2018-12-31 | $118.69 Million | +117.47% |
| 2017-12-31 | $54.58 Million | +12.30% |
| 2016-12-31 | $48.60 Million | +41.65% |
| 2015-12-31 | $34.31 Million | -27.89% |
| 2014-12-31 | $47.58 Million | +416.32% |
| 2013-12-31 | $9.21 Million | -39.29% |
| 2012-12-31 | $15.18 Million | +96.12% |
| 2011-12-31 | $7.74 Million | -76.42% |
| 2010-12-31 | $32.83 Million | +70.30% |
| 2009-12-31 | $19.28 Million | -26.48% |
| 2008-12-31 | $26.22 Million | -20.19% |
| 2007-12-31 | $32.85 Million | -26.81% |
| 2006-12-31 | $44.88 Million | +32.40% |
| 2005-12-31 | $33.90 Million | +86.60% |
| 2004-12-31 | $18.17 Million | +49.45% |
| 2003-12-31 | $12.15 Million | +5.21% |
| 2002-12-31 | $11.55 Million | -2.96% |
| 2001-12-31 | $11.90 Million | -11.40% |
| 2000-12-31 | $13.44 Million | +40.85% |
| 1999-12-31 | $9.54 Million | -22.90% |
| 1998-12-31 | $12.37 Million | -40.83% |
| 1997-12-31 | $20.91 Million | +13.65% |
| 1996-12-31 | $18.40 Million | +201.64% |
| 1995-12-31 | $6.10 Million | -- |
About Vericel Corp Ord
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the … Read more